BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

TapImmune Inc. 

2815 Eastlake Avenue East
Suite 300
Seattle  Washington  98102  U.S.A.
Phone: 866-359-7541 Fax: n/a


SEARCH JOBS




Industry
Biotechnology

Segment
Oncology
Vaccines





 Company News
TapImmune Inc. (TPIV) Announces $2 Million Registered Direct Offering 8/11/2014 10:42:10 AM
TapImmune Inc. (TPIV)'s New Clinical Trial In Advanced Stage Ovarian Cancer Expands The Use Of Folate Receptor Alpha Peptide Antigens 8/7/2014 11:08:05 AM
TapImmune Inc. (TPIV) Prevails In Legal Dispute With Michael Gardner 7/24/2014 10:53:30 AM
TapImmune Inc. (TPIV) Appoints Leading Immunotherapy Researcher to Chair Scientific Advisory Board 6/13/2014 7:29:08 AM
TapImmune Inc. (TPIV) Is Pleased To Provide An Update On Corporate Events And Milestones For 2014 4/3/2014 9:54:47 AM
TapImmune Inc. (TPIV) Is Pleased To Announce The Filing Of New Intellectual Property Surrounding Its Novel And Proprietary Platform Expression System Polystart™ 3/20/2014 10:12:31 AM
TapImmune Inc. (TPIV) Is Pleased To Announce The Signing Of An Exclusive Option Agreement For A New Phase 1 Clinical Program In Breast And Ovarian Cancer 3/19/2014 9:02:38 AM
TapImmune Inc. (TPIV) Releases Positive Interim Data On Phase I Clinical Trial In HER2/Neu+ Breast Cancer 3/3/2014 9:19:35 AM
TapImmune Inc. (TPIV) Chairman And CEO, Glynn Wilson, Ph.D. Provides Corporate Update On Company Progress 2/27/2014 9:57:52 AM
TapImmune Inc. (TPIV) Announces the Appointment of Sherry Grisewood to the Board of Directors 3/20/2013 9:21:21 AM
1234567